Physician profile
Larry Johnston
NPI 1386036333
$5,370.07
in general payments reported to CMS, 2019-2025
30 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $602 · 2021: $1,393 · 2022: $1,953 · 2023: $87.25 · 2024: $574 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,580.82 | 2021-2022 | |
| Abbvie INC. | $1,003.62 | 2020-2025 | |
| Qol Medical, LLC | $408.62 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $302.19 | 2019-2021 | |
| Janssen Biotech, INC. | $297.77 | 2020-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $226.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.82 | 2021-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $211.42 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.01 | 2021-2024 | Xifaxan |
| Boston Scientific Corporation | $164.32 | 2019-2024 | Resolution Clip |
| Gilead Sciences, INC. | $131.53 | 2022-2025 | |
| Medtronic, INC. | $117.11 | 2021 | |
| Ethicon US, LLC | $91.71 | 2021 | |
| Glaxosmithkline, LLC. | $79.97 | 2019 | |
| Intercept Pharmaceuticals, INC. | $52.89 | 2020-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $43.31 | 2020 | |
| Pfizer INC. | $32.46 | 2024 | |
| Novo Nordisk INC | $28.44 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $24.58 | 2021 | |
| Lilly USA, LLC | $24.40 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $22.27 | 2024 | Resmetirom |
| Ardelyx, INC. | $20.31 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $20.14 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.13 | 2025 | Iqirvo |
| Dova Pharmaceuticals | $17.74 | 2021 | |
| Celgene Corporation | $15.66 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $15.38 | 2021 | |
| Endo Pharmaceuticals INC. | $13.37 | 2020 | |
| Alfasigma USA, INC. | $12.65 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $11.57 | 2024 | Lockado, Lesionhunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.